MC4R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
In his 1987 book Spuren des Widerstands Die Bergarbeiterbewegung im Dritten Reich und im Exil (Traces of Resistance The Miners' Movement in the Third Reich and In Exile), Peukert began with the question "How does one write a history of continual failure?", which he answered with "To write a history of the resistance from the "loser's" viewpoint means trying to understand why, in spite of everything, they did not give up". Peukert argued even through the Social Democratic and Communist miners failed utterly in their attempts to overthrow the Nazi dictatorship, their willingness to take a stand, no matter how hopeless, and to suffer for their beliefs in the concentration camps meant that they should not be dismissed by historians as "losers". In the late 1980s, Peukert had been working on a project for a comprehensive alltagsgeschichte in Nazi Germany in northern Germany that was intended to be the counterpart to the "Bavaria project" led by Martin Broszat that sought to produce a comprehensive alltagsgeschichte in Nazi Germany in Bavaria.
Kipa-Williams thought it would be good to have a character that was not "a player" and instead he was shown wanting a committed relationship. Kipa-Williams gave viewers hope of a reconciliation for Ari and Mac, saying "I think there's always a chance for rekindling relationships. Mack has become quite hurt from it all though." Kipa-Williams said events surrounding the break-up would be "heartbreaking". He predicted tears would be shed and was interested in the audience reaction, adding "something happens that almost rips everyone apart..." Writers scripted a pregnancy for Mac, which she keeps secret from Ari as she decides whether or not to have an abortion. The decision is taken out of her hand when she suffers an ectopic pregnancy and miscarries. Mac returns to work at Salt, but when Ari turns up with Mia and attempts to talk to her, Mac cannot face being in the same room as him. Weir said it was "too painful" for Mac, who is "rattled" by his presence. Weir also said that Mac is feeling confused and abandoned by Ari. Shortly after, Mac collapses and Tane takes her to the hospital, where Ari, who has learned the truth about the pregnancy, comforts her as she cries in his arms.
=== Neuronal membrane === The brain preferentially uses choline to synthesize acetylcholine. This limits the amount of choline available to synthesize phosphatidylcholine. When the availability of choline is low or the need for acetylcholine increases, phospholipids containing choline can be catabolized from neuronal membranes. These phospholipids include sphingomyelin and phosphatidylcholine. Supplementation with citicoline can increase the amount of choline available for acetylcholine synthesis and aid in rebuilding membrane phospholipid stores after depletion. Citicoline decreases phospholipase stimulation. This can lower levels of hydroxyl radicals produced after an ischemia and prevent cardiolipin from being catabolized by phospholipase A2. It can also work to restore cardiolipin levels in the inner mitochondrial membrane.
Sources: en.wikipedia.org
=== EU resources === "The "hormone" case: Background and history". The 2000 Queluz EU-US Summit, 2000-05-31. European Commission Commissioner for External Relations. 24 May 2000. Archived from the original on 6 March 2008.
== Rivalries == The club's fans share a fierce and often violent rivalry with the supporters of Chemie Leipzig. When both teams met in the quarter finals of the Sachsenpokal in 2016, German daily newspaper Die Welt called the match the "German hooligan summit". An additional reason for the enmity between some fan groups (namely their ultras) is a political one. Whereas certain Chemie fan clubs express left-wing and anti-fascist political views, Lok has vocal supporters from the right and far-right of the political spectrum. Lok also have lesser local rivalry with RB Leipzig.
Formation of Compound I: APX reacts with H2O2 to form Compound I - where the heme is oxidized to Fe4+ = O (oxyferryl). This produces a porphyrin pi-organic cation radical. APX + H2O2 → Compound I + H2O [1] Formation of Compound II: Through a one electron reduction, Compound I is reduced by substrate (HS) to form Compound II; Compound II accepts a second electron from ascorbate to regenerate the ferric resting state. This is s sequential single-electron transfer steps. Compound I + HS → Compound II + S• [2] Compound II + HS → APX + S• + H2O [3] In ascorbate peroxidase, Compound I is a transient (green) species and contains a high-valent iron species (known as ferryl heme, FeIV) and a porphyrin pi-cation radical, as found in horseradish peroxidase. Compound II contains only the ferryl heme. Spectroscopic and kinetic work on plant APXs supports these intermediates and sequential one electron transfers.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.